Results 71 to 80 of about 5,235,169 (235)

Switching Long‐Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1‐Year OASISplus Results

open access: yesAllergy, EarlyView.
This study evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes. Patients who switched from LTP to donidalorsen experienced a 67.6% reduction in HAE attack rates over 52 weeks.
Marc A. Riedl   +16 more
wiley   +1 more source

The Relationship Between Stress and Anxiety with the Occurrence of Functional Dyspepsia among Medical Students of Sumatera Utara University

open access: yesThe Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Background: Functional dyspepsia is characterized by upper gastrointestinal symptoms like epigastric bloating, pain, and early satiation without structural disease evidence, including negative findings on endoscopy. Psychological triggers, such as stress
Tri Mulyani Aries, Imelda Rey
doaj   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman   +3 more
wiley   +1 more source

Prevalence and Risk Factors of Functional Dyspepsia: A Population-Based Study

open access: yesThe Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Background: Functional dyspepsia is one of the most common functional gastrointestinal disorders and affects more than 20% of the population. This study aimed to determine the prevalence of functional dyspepsia according to Rome IV criteria and its ...
Selami Aydın   +3 more
doaj   +1 more source

Gut Microbiota Dysbiosis in Functional Dyspepsia

open access: yesMicroorganisms, 2020
Functional dyspepsia (FD) is one of the most prevalent chronic functional gastrointestinal disorders. Several distinct pathophysiological mechanisms, including gastro duodenal motor disorders, visceral hypersensitivity, brain-gut interactions, duodenal ...
G. Tziatzios   +6 more
semanticscholar   +1 more source

Dyspepsia, functional dyspepsia and Rome IV criteria

open access: yesRevista Española de Enfermedades Digestivas, 2018
We present a number of comments about the recently published paper by Aziz et al. about the epidemiology of Functional Dyspepsia in USA, Canada and UK in comparison with previous studies in our country.
Caballero-Mateos, Antonio M ª   +1 more
openaire   +3 more sources

Prevalence and association of functional dyspepsia in the elderly patients: a systematic review and meta-analysis

open access: yesThe Aging Male
Background In the elderly, diagnosing and treating functional dyspepsia may be more challenging. The objectives of the study were to evaluate the prevalence and association of functional dyspepsia in adult individuals and elderly populations (especially ≥
Hui Guo   +3 more
doaj   +1 more source

Review: Functional dyspepsia

open access: yesTherapeutic Advances in Gastroenterology, 2010
Dyspepsia is a common term used for a heterogeneous group of abdominal symptoms. Functional dyspepsia (FD) is the focus of this review. The 2006 Rome III criteria defined FD and its subgroups, postprandial distress syndrome (PDS) and epigastric pain ...
Rita Brun MD, Braden Kuo MD
doaj   +1 more source

Guideline Recommendation for Endpoints Used in Clinical Trials for Functional Dyspepsia

open access: yesThe Korean Journal of Gastroenterology, 2018
Functional dyspepsia is a disease, in which there is no organic lesion but chronic and repetitive postprandial fullness, early satiation, epigastric pain, and epigastric burning. Functional dyspepsia is not life-threatening but its symptoms are relapsing
Han Hee Lee   +2 more
doaj   +1 more source

Efficacy and Safety of Fixed‐Dose Combinations of Sitagliptin and Empagliflozin as Add‐On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Multi‐Centre, Placebo‐Controlled, Phase III Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Type 2 diabetes mellitus (T2DM) is a progressive, multi‐organ disorder that often requires intensive combination therapy. This Phase III, randomised, double‐blind, placebo‐controlled study evaluated the efficacy and safety of two fixed‐dose combinations (FDCs) of sitagliptin 100 mg with empagliflozin 10 mg (DW1026C1) or ...
Soo Lim   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy